JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Phase 3

Recruiting

Conditions: Depressive Disorder, Major
Anhedonia

Interventions: Drug: Aticaprant
Other: Placebo

First Posted Date: 2022-09-22

Last Posted Date: 2024-12-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 710

Registration Number: NCT05550532

Locations: 🇦🇷
Centro Medico Luquez, Cordoba, Argentina
🇦🇷
INSA Instituto de Neurociencias San Agustín, La Plata, Argentina
🇦🇷
Clinica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Argentina

and more 126 locations

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: JNJ-88260237

First Posted Date: 2022-09-15

Last Posted Date: 2023-06-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT05541315

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: Guselkumab Dose 1
Other: Placebo
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 3

First Posted Date: 2022-09-06

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 418

Registration Number: NCT05528510

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇰🇷
Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 232 locations

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cosentyx
Drug: Candin

First Posted Date: 2022-08-31

Last Posted Date: 2022-11-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 20

Registration Number: NCT05522517

Locations: 🇧🇪
Clinical Pharmacology Unit, Antwerpen, Belgium

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1

Withdrawn

Conditions: Acute Leukemias
Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: JNJ-75276617
Drug: Fludarabine
Drug: Cytarabine
Drug: Intrathecal Chemotherapy
Drug: Dexamethasone
Drug: Vincristine
Drug: Pegaspargase

First Posted Date: 2022-08-30

Last Posted Date: 2024-08-22

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05521087

Locations: 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 8 locations

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Phase 3

Recruiting

Conditions: Depressive Disorder, Major

Interventions: Drug: Aticaprant

First Posted Date: 2022-08-26

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 840

Registration Number: NCT05518149

Locations: 🇺🇸
University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
SW Biomedical Research LLC, Tucson, Arizona, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States

and more 193 locations

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

First Posted Date: 2022-08-16

Last Posted Date: 2024-01-05

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05503550

Locations: 🇸🇮
DUMMY, Dummy, Slovenia

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Carcinoma, Non-small-Cell Lung

Interventions: Drug: Amivantamab
Drug: Lazertinib
Drug: Carboplatin
Drug: Direct Oral Anticoagulant (DOAC)
Drug: Pemetrexed
Drug: Low Molecular Weight Heparin (LMWH)

First Posted Date: 2022-08-12

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 390

Registration Number: NCT05498428

Locations: 🇧🇷
Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
🇧🇷
Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Brazil
🇧🇷
Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil

and more 101 locations

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Capmatinib
Drug: Amivantamab

First Posted Date: 2022-08-04

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 57

Registration Number: NCT05488314

Locations: 🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

and more 73 locations

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Conditions: Relapsed or Refractory Multiple Myeloma

First Posted Date: 2022-07-19

Last Posted Date: 2022-11-15

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05463939

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy